SOURCE: AspenBio Pharma, Inc.

May 12, 2008 13:39 ET

AspenBio Pharma to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

CASTLE ROCK, CO--(Marketwire - May 12, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco May 19-20, 2008.

AspenBio's President and CEO Richard Donnelly, is scheduled to present at 12:50 p.m. on Monday, May 19, 2008 in the Atlantique Salon. A live webcast and replay of the presentation will be available at

Mr. Donnelly will discuss the continued advancement of its pre-clinical trials for AppyScore™, the world's first blood-based screening/triage test for human appendicitis, which are being conducted in preparation for a late 2008 FDA 510(k) filing. He will also talk about the exclusive license and commercialization agreement AspenBio recently signed with Novartis Animal Health, Inc. for the development and worldwide launch of AspenBio's novel bovine reproduction drugs, BoviPure LH™ and BoviPure FSH™.

Now in its fifth year, the Rodman & Renshaw Annual Global Healthcare Conference features presentations by more than 175 emerging growth biotechnology companies at an event that rapidly has become the premier event on the Life Sciences calendar. Companies will share their accomplishments on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. The Conference offers emerging life sciences companies a unique platform to command the attention of industry-leading institutional investors, venture capitalists, sophisticated private investors, and business development & partnering executives.

About Rodman & Renshaw, LLC

Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. During the last two years Rodman & Renshaw completed over 60 financing transactions, totaling over $1 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical and diagnostic company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to some of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use in animals of economic importance. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out acute appendicitis in patients complaining of abdominal pain. For more information, go to

Contact Information

  • Contacts
    AspenBio Pharma, Inc.
    Gregory Pusey
    Tel 303-722-4008

    Investor Relations
    Liolios Group, Inc.
    Scott Liolios or Ron Both
    Tel 949-574-3860